China Shineway Pharmaceutical Group Limited (C1S) - Net Assets
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) has net assets worth €8.06 Billion EUR (≈ $9.43 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.78 Billion ≈ $12.60 Billion USD) and total liabilities (€2.72 Billion ≈ $3.17 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check C1S intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €8.06 Billion |
| % of Total Assets | 74.8% |
| Annual Growth Rate | 5.12% |
| 5-Year Change | 36.61% |
| 10-Year Change | 43.28% |
| Growth Volatility | 3.89 |
China Shineway Pharmaceutical Group Limited - Net Assets Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's net assets have evolved over time, based on quarterly financial data. See China Shineway Pharmaceutical Group Limi (C1S) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below shows the annual net assets of China Shineway Pharmaceutical Group Limited from 2013 to 2025. For live valuation and market cap data, see market cap of China Shineway Pharmaceutical Group Limi.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €8.06 Billion ≈ $9.43 Billion |
+7.97% |
| 2024-12-31 | €7.47 Billion ≈ $8.73 Billion |
+6.14% |
| 2023-12-31 | €7.03 Billion ≈ $8.22 Billion |
+10.22% |
| 2022-12-31 | €6.38 Billion ≈ $7.46 Billion |
+8.15% |
| 2021-12-31 | €5.90 Billion ≈ $6.90 Billion |
+1.85% |
| 2020-12-31 | €5.79 Billion ≈ $6.77 Billion |
+0.30% |
| 2019-12-31 | €5.78 Billion ≈ $6.75 Billion |
+0.19% |
| 2018-12-31 | €5.77 Billion ≈ $6.74 Billion |
-0.95% |
| 2017-12-31 | €5.82 Billion ≈ $6.81 Billion |
+3.45% |
| 2016-12-31 | €5.63 Billion ≈ $6.58 Billion |
+6.24% |
| 2015-12-31 | €5.30 Billion ≈ $6.19 Billion |
+8.24% |
| 2014-12-31 | €4.89 Billion ≈ $5.72 Billion |
+10.46% |
| 2013-12-31 | €4.43 Billion ≈ $5.18 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to China Shineway Pharmaceutical Group Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 110.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €7.32 Billion | 90.79% |
| Other Components | €742.27 Million | 9.21% |
| Total Equity | €8.06 Billion | 100.00% |
China Shineway Pharmaceutical Group Limited Competitors by Market Cap
The table below lists competitors of China Shineway Pharmaceutical Group Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Qiaoyin Environmental Tech Co Ltd
SHE:002973
|
$724.19 Million |
|
Paul Hartmann AG
F:PHH2
|
$724.56 Million |
|
Ningbo Techmation Co Ltd
SHG:603015
|
$724.59 Million |
|
Shakti Pumps (India) Limited
NSE:SHAKTIPUMP
|
$724.70 Million |
|
Ray Sigorta AS
IS:RAYSG
|
$723.89 Million |
|
FastPartner AB (publ)
ST:FPAR-A
|
$723.85 Million |
|
Anel Elektrik Proje Taahhut ve Ticaret AS
IS:ANELE
|
$723.51 Million |
|
Oneness Biotech Co Ltd
TWO:4743
|
$723.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China Shineway Pharmaceutical Group Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,466,904,000 to 8,061,814,000, a change of 594,910,000 (8.0%).
- Net income of 949,948,000 contributed positively to equity growth.
- Dividend payments of 355,038,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €949.95 Million | +11.78% |
| Dividends Paid | €355.04 Million | -4.4% |
| Total Change | €- | 7.97% |
Book Value vs Market Value Analysis
This analysis compares China Shineway Pharmaceutical Group Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €7.04 | €0.82 | x |
| 2018-12-31 | €6.97 | €0.82 | x |
| 2019-12-31 | €6.99 | €0.82 | x |
| 2020-12-31 | €7.01 | €0.82 | x |
| 2021-12-31 | €7.14 | €0.82 | x |
| 2022-12-31 | €7.72 | €0.82 | x |
| 2023-12-31 | €8.51 | €0.82 | x |
| 2024-12-31 | €9.88 | €0.82 | x |
| 2025-12-31 | €10.67 | €0.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China Shineway Pharmaceutical Group Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.78%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.30%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.34x
- Recent ROE (11.78%) is above the historical average (10.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 15.44% | 31.26% | 0.38x | 1.30x | €240.74 Million |
| 2014 | 14.41% | 31.62% | 0.38x | 1.21x | €215.53 Million |
| 2015 | 12.42% | 32.02% | 0.33x | 1.16x | €128.31 Million |
| 2016 | 10.47% | 29.56% | 0.31x | 1.15x | €26.53 Million |
| 2017 | 7.76% | 23.52% | 0.29x | 1.15x | €-130.54 Million |
| 2018 | 8.77% | 19.68% | 0.38x | 1.17x | €-70.70 Million |
| 2019 | 8.71% | 18.59% | 0.38x | 1.23x | €-74.54 Million |
| 2020 | 5.09% | 11.11% | 0.37x | 1.24x | €-284.39 Million |
| 2021 | 9.43% | 17.27% | 0.45x | 1.22x | €-33.47 Million |
| 2022 | 11.32% | 18.30% | 0.48x | 1.29x | €84.52 Million |
| 2023 | 13.78% | 21.47% | 0.47x | 1.36x | €266.03 Million |
| 2024 | 11.25% | 22.24% | 0.38x | 1.34x | €93.36 Million |
| 2025 | 11.78% | 30.30% | 0.29x | 1.34x | €143.77 Million |
Industry Comparison
This section compares China Shineway Pharmaceutical Group Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,659,440,547
- Average return on equity (ROE) among peers: -44.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China Shineway Pharmaceutical Group Limited (C1S) | €8.06 Billion | 15.44% | 0.34x | $724.18 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $48.38 Billion | 9.77% | 0.93x | $1.13 Billion |
| PEPTONIC MEDICAL (28L) | $48.55 Million | -123.64% | 0.45x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $7.85 Billion | 28.40% | 0.37x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $2.69 Million | -197.11% | 3.73x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $170.06 Million | -9.56% | 0.06x | $157.72 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.83 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-815.79K | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $26.34 Million | -20.49% | 0.14x | $7.31 Million |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $73.36 Million |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more